In vitro antimycobacterial activity evaluation of a new lead compound (LQFM326) against clinical strains of Mycobacterium sp.

Abstract

Tuberculosis (TB) remains a significant global public health challenge. The novel compound LQFM326 was evaluated for its antimycobacterial activity against seven Mycobacterium species. Minimum inhibitory concentrations (MICs) were determined, revealing values of 15.6 μg/mL against Mycobacterium tuberculosis H37Ra and 12.5 μg/mL against clinical strains. The MIC values observed for these reference antimicrobials against M. tuberculosis H37Ra were 0.25 μg/mL for rifampicin and 0.125 μg/ mL for isoniazid. Surface damage to Mycobacterium abscessus cells was observed via scanning electron microscopy (SEM), confirming morphological alterations induced by LQFM326. Cellular viability was assessed using the Live/Dead assay, with a CC50 of 126.68 ± 42.66 μg/mL. The selectivity index (SI), calculated from MIC and CC50 values, ranged from 2.03 to 10.13, with values above 10 indicating favorable selectivity. Additionally, synergistic effects were observed when LQFM326 was combined with other antibiotics. These findings highlight LQFM326 as a promising antimycobacterial agent with potential efflux-inhibitory and synergistic properties. Further studies are needed to validate its efficacy across diverse clinical strains and to elucidate its mechanism of action